Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Botulinum toxin is a potent neurotoxic protein produced by the bacterium *Clostridium botulinum* and related species. It acts as a zinc-dependent endopeptidase that specifically cleaves SNARE proteins (such as SNAP-25 or synaptobrevin) within peripheral cholinergic nerve terminals. This cleavage prevents the fusion of acetylcholine-containing vesicles with the presynaptic membrane, thereby inhibiting the release of acetylcholine and causing temporary muscle paralysis or inhibition of sweat gland activity. In clinical practice, various formulations (e.g., onabotulinumtoxinA, abobotulinumtoxinA) are used for a wide range of indications, including muscle spasticity, cervical dystonia, chronic migraine, and hyperhidrosis. In the context of localized epidermolysis bullosa simplex (LEBS), botulinum toxin injections are evaluated for their ability to reduce sweating (hyperhidrosis), which is a major trigger for friction-induced blistering in these patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on botulinum toxin.